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F AMILIAL amyloidotic polyneuropathy (FAP) is an inherited autosomal dominant systemic disease caused 
by an abnormal protein-the Transthyrretin Methionine 30 
(TTR Met 30, in the Portuguese variety-methionine in- 
stead of valine). This abnormality is caused by a mutant 
gene in the 18th chromosome pair, and the main site of 
production of the TTR Met 30 is the liver (more than 90%). 
There are a good number of mutants. The largest affected 
populations are located in Portugal, Sweden, and Japan. 
The disease becomes clinically apparent in the third decade 
(for the Portuguese variety) and inevitably progresses to 
death in 10 to 14 years.‘T2,’ 
Liver transplantation (LTx) drastically reduces the serum 
levels of the abnormal protein in a permanent way. Thus, it 
is expected that LTx stops the progression of the disease 
and, actually, it seems the most promising therapy. Since 
the first experience by Holmgren, in 1990, almost 200 cases 
of FAP patients have been transplanted worldwide. Stabi- 
lization of the disease and regression of some symptoms 
have been repeatedly reported!,’ Besides the production of 
the abnormal protein, no other liver functional disturbance 
is known and the liver of these patients is anatomically 
normal. This makes hepatectomy easier than the same 
procedure with anatomically diseased livers. Given the 
organ shortage, the use of these livers adequately harvested 
for implantation in other patients is appealing. 
RATIONALE 
The logical basis for the use of FAP livers for transplanta- 
tion in other patients are multiple: the livers are anatomi- 
cally normal and show no other functional abnormalities 
than the TTR Met 30 production; the hepatectomy affords 
liver grafts in the best conditions; the disease requires at 
least 20 years to develop symptoms in the genetically 
affected individuals; and it is expected that the TTR Met 30 
producing grafts in genetically non-affected patients will 
need at least the same time to develop symptoms or, more 
optimistically, will never generate the disease. The most 
obvious candidates for this sequential or “domino” liver 
transplantation (SLTx, DLTx) are (at least at the moment), 
patients with hepato-carcinoma or metastatic disease con- 
fined to the liver, not adequate for surgical resection and 
not accepted in the overloaded waiting lists. 
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MATERIALS, METHODS AND RESULTS 
After full agreement of the Ethical Committee of the HUC, 
we started DLTx strategy in October 1995. Till now, four 
advanced oncological patients have received 4 FAP livers 
retrieved from 4 female adult patients who received 4 
cadaver liver grafts. The recipients of the FAP livers were 4 
males, 56,51,44, and 48 years old, respectively with isolated 
hepatic metastasis of a resected carcinoma of the sigmoid, 
hepatocellular carcinoma associated to posthepatitis C cir- 
rhosis, primary hepatocellular carcinoma and, a last patient, 
with isolated liver metastasis from a previously excised 
pancreatic neuroendocrine carcinoma. Patient 1 was 
treated with systemic and intrarterial chemotherapy before 
transplantation, patient 2 received 3 courses of doxoru- 
bicine post-transplantation, patient 3 had been treated with 
intrarterial chemoembolization, and patient 4 had received 
systemic chemotherapy for several months in another coun- 
try. The work-up of all patients included abdominal, tho- 
racic, and cranial CT scans, NMR, angiographies, and 
exploratory laparatomies with lymph node biopsies. 
The main points of the hepatectomy technique in the 
FAP patients for these SLTx were: use of the external 
veno-venous by-pass with bio-pump; dissection of the su- 
pra-hepatic vena cava above the diaphragmatic fibrotic ring 
which was divided; dissection of the main hepatic bile duct 
and hepatic artery limited to a minimum; division of the 
hepatic artery at the emergence of the gastroduodenal 
artery; division of the vena porta half a centimeter beneath 
its bifurcation. 
The orthotopic implantation of the FAP liver grafts in the 
oncological recipients followed the classical technique (with 
external veno-venous by-pass) in patients 1 and 3 a “piggy- 
back” variant in the others (without veno-venous by-pass). 
No particularly important technical difficulties were raised. 
Only in patient 3 was there a relevant complication: stenosis 
of the arterial anastomosis favored by a severe periaortic 
inflamatory reaction secondary to chemoembolization 
which caused complete thrombosis of the distal celiac trunk. 
Successful rearterialization of the liver was attained 
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through the right renal artery, the kidney being autotrans- 
planted. In patient 2, the supra-hepatic vena-cava was too 
short and had to be reconstructed before the anastomosis. 
Patient 4 developed a biliary leakage which was surgically 
repaired. All patients show very good general condition and 
normal liver function at 10, 9, 3, and 2 months posttrans- 
plantation. Patient 1 alfa-feto-protein increased quite re- 
cently and a lung metastasis has been detected. All the 
F.A.P. donors had a normal evolution post-OLTx. 
DISCUSSION 
The shortage of cadaveric organs for transplantation has led 
to important developments in this field, the use of reduced 
liver grafts, and segmental living donor grafts being the 
most remarkable. FAP is a progressive incapacitating dis- 
ease leading to death during the normally most active 
period of life. The only highly promising therapy, at the 
moment, is liver transplantation. The hope that this treat- 
ment generated rapidly spread among the more than one 
thousand patients who, only in Portugal, may be suitable 
candidates for aL TX. Through diligent procurement and 
fair allocation of cadaver grafts we estimate that about 50 
FAP patients per year may be transplanted in Portugal. This 
means an additional pool of 50 liver grafts, anatomically 
normal and also functionally normal, except for the produc- 
tion of the abnormal protein, capable of causing the sys- 
temic amyloidosis. However, the minimum time for this 
disease to show its first symptoms, in the genetically affected 
patient is at least 20 years and it usually courses to death in 
a lo- to 1Cyear period. Whether it will follow the same 
course in a nongenetically affected person is not known. 
The observation that the deposits of the TTR Met 30 in 
the nerves may not be the primary cause for this amyloid- 
osis provides some support for more optimistic view over 
the future of the non-genetically individual receiving liver 
grafts from FAP patients.‘.’ Whatever the case, the use of 
FAP livers as grafts for some oncological patients with a 
short life expectancy seemed to us an ethically acceptable 
option. Those candidates should have malignancies con- 
fined to the livers and not amenable to surgical resection 
and life expectancy independent of the malignancy should 
be less than 30 years, this is the minimum total time for the 
disease to develop and to cause death in the genetically 
affected patients. Our four transplanted patients would not 
be accepted in any national list for LTx. These criteria for 
inclusion were fully accepted by the independent Ethical 
Committee of the HUC and supported by specialized legal 
advise. All patients (both FAP’s and oncological recipients) 
received detailed informations about the procedures. The 
main principle presiding to this experience regarded the 
safety of the procedures in the FAP patients, so that no 
additional risk should be imposed on them by this strategy. 
The biochemical and clinical consequences of the use of 
these livers must wait a long time while expecting that some 
of these patients live long enough. The immediate hepatic 
function had been very good as well as the recovery of all 4 
patients till now submitted to this transplant. The TTR Met 
30 appeared almost immediately in their blood and so it 
may become a trustful marker of the initial liver function of 
the transplant. In the future, new insights on the pathogen- 
esis of FAP may come out of this strategy. 
In summary, DLTx using FAP patients’ livers is an 
ethically sound strategy that may afford opportunities to 
transplant some patients otherwise without access to this 
therapy. It has been a safe procedure for the FAP donors 
without complications ascribable to specific technical prob- 
lems. All FAP liver grafts showed very good immediate 
function. None of these patients has shown any symptoms 
of FAP despite the quick appearance of TTR Met 30 in 
their blood after DLTx. 
An extended follow-up of the long-term survivals is 
required to get some answers for the questions raised by 
this new strategy. 
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